Dina Sabry

Citation:

Sayyed, H. G., A. Osama, N. K. Idriss, D. Sabry, A. S. Abdelrhim, and R. Bakry, "Comparison of the therapeutic effectiveness of human CD34(+) and rat bone marrow mesenchymal stem cells on improvement of experimental liver fibrosis in Wistar rats.", International journal of physiology, pathophysiology and pharmacology, vol. 8, issue 3, pp. 128-139, 2016.

Abstract:

BACKGROUND AND OBJECTIVE: Human umbilical cord blood (UCB) cells and bone marrow mesenchymal stem cells (BM-MSCs) have numerous advantages as grafts for cell transplantation. We hypothesized differing impacts of human UCB cells and rat BM-MSCs on reversal of hepatic injury and revival of liver function in carbon tetrachloride (CCl4)-induced liver fibrosis.

METHODS: Forty rats were divided into 4 groups; control group, CCl4 group, CCl4/CD34(+) group and CCl4/BM-MSCs group. Blood samples were driven from rats at 4, 8 and 12 weeks to measure serum concentration of albumin and alanine aminotransferase (ALT). Quantitative expression of collagen Iα, TGF-β, α-SMA, albumin, MMP-2, MMP-9 and TNF-α were assessed by polymerase chain reaction. Histopathological examination of the liver tissue was performed. GFP labeled cells were detected in groups injected with stem cells.

RESULTS: Regarding liver function, CD34(+) were more efficient than BM-MSCs in elevating albumin (P<0.05) and reducing ALT (P<0.05) concentrations. Concerning gene expression, CD34(+) were more effective than BM-MSCs in reducing gene expressions of collagen Iα (P<0.01), TGF-β1 (P<0.01) and α-SMA (P<0.01). Both CD34(+) and BM-MSCs have the same efficacy in reducing TNF-α (P<0.001 and P<0.01, respectively). Furthermore, CD34(+) were more valuable than BM-MSCs in increasing gene expression of albumin (P<0.05) and MMP-9 (P<0.01).

CONCLUSION: Taken together; human UCB CD34(+) stem cells were more efficient in improvement of experimental liver injury than BM-MSCs. This study highlighted an important role of human UCB CD34(+) stem cells in liver fibrosis therapy.